Faeth Therapeutics (FTH) holder files to sell 130K shares under Rule 144

Rhea-AI Filing Summary

Cambrian Biopharma, Inc., as a holder of Faeth Therapeutics, Inc. common stock, has filed to sell up to 130,142 shares of Faeth Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ, with a stated value of $3,642,675.00, beginning on or after July 22, 2026.

The filing also notes that during the past three months, Cambrian Biopharma sold 25,000 shares of Faeth Therapeutics common stock for $500,548.39 on June 1, 2026. The securities being sold were originally acquired in a private placement dated January 10, 2020 for cash.

Key Figures

Planned shares to be sold: 130,142 shares Stated value of planned sale: $3,642,675.00 Recent shares sold: 25,000 shares +2 more

5 metrics

Planned shares to be sold 130,142 shares Common stock sale planned on or after July 22, 2026

Stated value of planned sale $3,642,675.00 Aggregate value associated with 130,142 shares of common stock

Recent shares sold 25,000 shares Common stock sold on June 1, 2026 within prior three months

Proceeds from recent sale $500,548.39 Consideration received for 25,000 shares sold on June 1, 2026

Earliest sale date 07/22/2026 Date on or after which planned NASDAQ sales may occur

Key Terms

Form 144, Rule 144, private placement, NASDAQ

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"144: Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

private placement financial

"Common | 01/10/2020 | Private Placement | Issuer"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

NASDAQ market

"07/22/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

What does Faeth Therapeutics (FTH) Form 144 disclose?

The filing discloses that Cambrian Biopharma intends to sell up to 130,142 shares of Faeth Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ beginning on or after July 22, 2026, under Rule 144.

How many Faeth Therapeutics (FTH) shares are planned for sale?

Cambrian Biopharma plans to sell up to 130,142 shares of Faeth Therapeutics common stock. The filing lists an aggregate value of $3,642,675.00 for these shares, with sales expected to occur on or after July 22, 2026 on NASDAQ.

Who is selling Faeth Therapeutics (FTH) shares under this Form 144?

The selling security holder is Cambrian Biopharma, Inc., using Fidelity Brokerage Services LLC as the broker. The issuer of the securities is Faeth Therapeutics, Inc., whose common stock is listed for trading on NASDAQ.

What prior sales of Faeth Therapeutics (FTH) shares are reported?

The filing reports that on June 1, 2026, Cambrian Biopharma sold 25,000 shares of Faeth Therapeutics common stock for total consideration of $500,548.39. This transaction occurred within the three-month period preceding the new planned sales.

How were the Faeth Therapeutics (FTH) shares originally acquired?

The shares being sold were originally acquired in a private placement on January 10, 2020. The Form 144 states that the acquisition consideration was cash/check and identifies the transaction as a private placement by the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 12:53 PM Accepted by SEC EDGAR 08/11/2026 - 12:52 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	130142	3642675.00	1340281	07/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/10/2020	Private Placement	Issuer			130142	01/10/2020	Cash/Check

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Cambrian Biopharma, Inc. 701 TILLERY STREET #12 #1010 AUSTIN TX 78702	Faeth Therapeutics, Inc.	06/01/2026	25000	500548.39

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)